Chest
Volume 138, Issue 4, Supplement, October 2010, Page 840A
Journal home page for Chest

Slide Presentations
Tuesday, November 2, 2010
Safety and Efficacy of Bosentan in Combination With Sildenafil in PAH Patients Who Experience Inadequate Clinical Response to Monotherapy: The COMPASS-3 Study

https://doi.org/10.1378/chest.10295Get rights and content

Section snippets

Abstract

PURPOSE: Combination therapy may improve outcomes in patients with severe pulmonary arterial hypertension (PAH). However, the appropriate time and functional thresholds to initiate such an approach are ill-defined. COMPASS-3 assessed the benefits of a bosentan-based stepped approach utilizing a 6-minute walk distance (6MWD) threshold of 380m as the functional threshold.

METHODS: Treatment-naive PAH patients with a baseline (BL) 6MWD of 150-360m were enrolled. Patients received bosentan for 16

References (0)

Cited by (0)

View full text